Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-03
2011-05-03
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S111000, C546S113000, C546S122000, C546S268100, C548S159000, C548S247000, C548S335100, C548S453000, C548S950000, C549S059000, C549S356000, C549S429000, C549S505000
Reexamination Certificate
active
07935725
ABSTRACT:
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
REFERENCES:
patent: 5585492 (1996-12-01), Chandrakumar et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5719306 (1998-02-01), Chandrakumar et al.
patent: 5723492 (1998-03-01), Chandrakumar et al.
patent: 6407140 (2002-06-01), Gregory et al.
patent: 6506876 (2003-01-01), Chandrakumar et al.
patent: 6559140 (2003-05-01), Bennani et al.
patent: 2003/0004191 (2003-01-01), Gregory et al.
patent: 2005/0043355 (2005-02-01), Gregory et al.
patent: 2005/0043378 (2005-02-01), Bembenek et al.
patent: 2005/0043379 (2005-02-01), Bembenek et al.
patent: 2006/0074121 (2006-04-01), Chen et al.
patent: 2007/0079078 (2007-04-01), Fujita et al.
patent: 2007/0155726 (2007-07-01), Arnaiz et al.
patent: 0266576 (1988-05-01), None
patent: WO 01/81347 (2001-01-01), None
patent: WO 2004/103959 (2004-12-01), None
patent: WO 2006/004475 (2006-01-01), None
patent: WO 2007/007069 (2007-01-01), None
patent: WO 2007/079078 (2007-07-01), None
Wang, S. et al. A Novel Hepatointestinal Leukotriene B4 Receptor. Cloning and Functional Characterization. J. Biol. Chem. 2000, 275(52), 40686-40694.
Weiner, H.L., et al. Inflammation and Therapeutic Vaccination in CNS Diseases. Nature (London) 2002, 420(6917), 879-884.
Willemsen M.A. et al. Clinical and biochemical effects of zileuton in patients with the Sjogren-Larsson syndrome. Eur J Pediatr. 2001,160, 711-717.
Woodmansee D.P. et al. Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol. 1999, 83, 548-552.
Yokomizo, T. et al. Leukotriene A4 Hydrolase and Leukotriene B4 Metabolism. J. Lipid Mediat. Cell Signal. 1995, 12(2-3), 321-332.
Yokomizo, T. et al. A Second Leukotriene B4 Receptor, BLT2: A New Therapeutic Target in Inflammation and Immunological Disorders. J. Exp. Med. 2000, 192(3), 421-431.
Yokomizo, T. et al. Co-expression of two LTB4 Receptors in Human Mononuclear Cells. Life Sci. 2001, 68(19-20), 2207-2212.
Yokomizo, T. et al. Leukotriene B4: Metabolism and Signal Transduction. Arch. Biochem. Biophys. 2001, 385(2), 231-241.
Zhu, Y.I. et al. Preview of Potential Therapeutic Applications of Leukotriene B4 Inhibitors in Dermatology. Skin Pharmacol. Appl. Skin Physiol. 2000, 13(5), 235-245.
Zhu, L. et al. A convenient synthesis of 2-mercapto and 2-chlorobenzothiazoies, J. Heterocyclic Chem. 2005, 42, 727-730.
Zouboulis, Ch.C. et al. Zileuton, an Oral 5-Lipoxygenase Inhibitor, Directly Reduces Sebum Production. Dermatology 2005, 210(1), 36-38.
Zouboulis, Ch.C. et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch. Dermatol. 2003, 139(5), 668-670.
Cohen, J. The Immunopathogenesis of Sepsis. Nature (London) 2002, 420(6917), 885-891.
Coussens, L.M. et al. Inflammation and Cancer. Nature (London) 2002, 420(6917), 860-867.
Crooks, S.W. and R.A. Stockley. Leukotriene B4. Int. J. Biochem. Cell Biol. 1998, 30(2), 173-178.
Cunha, J.M. et al. The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br. J. Pharmacol. 2003, 139(6), 1135-1145.
Ellis, C.N. et al. Cost of atopic dermatitis and eczema in the United States. J. Am. Acad. Dermatol. 2002, 46, 361-370.
Emingil, G. et al. Levels of leukotriene B4 in gingival crevicular fluid and gingival tissue in specific periodontal diseases. J. Periodontol. 2001, 72(8), 1025-1031.
Fitzpatrick, F.A. et al. Effects of Leukotriene A4on Neutrophil Activation. Ann. N. Y. Acad. Sci. 1994, 714, 64-74.
Ford-Hutchinson, A.W. et al. 5-Lipoxygenase. Ann. Rev. Biochem.1994, 63, 383-417.
Fleisher, D. et al. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Advanced Drug Delivery Reviews, 1996, 19, 115-130.
Friedrich E.B. et al. Mechanisms of leukotriene B4-triggered monocyte adhesion. Arterioscler Thromb Vasc Biol 2003, 23, 1761-1767.
Funk et al. Molecular Cloning and Amino Acid Sequence of Leukotriene A4 Hydrolase. PNAS 1987, 84, 6677-6681.
Gelfand, E.W. et al. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol. 2006, 117(3), 577-582.
Gierse et al. High level Experssion and Purification of Human Leukotriene A4 Hydrolase from Insect Cells Infected with a Baculovirus Vector. Protein Expression and Purification, 1993, 4, 358-366.
Gompertz, S. et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 2001, 17(6), 1112-1119.
Goodarzi, K. et al. Leukotriene B4 and BLT1 Control Cytotoxic Effector T Cell Recruitment to Inflamed Tissues. Nat. Immunol. 2003) 4(10), 965-973.
Griffiths, R.J. et al. Leukotriene B4Plays a Critical Role in the Progression of Collagen-Induced Arthritis. PNAS 1995, 92(2), 517-521.
Hakonarson, H. et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. A randomized trial. JAMA 2005, 293(18), 2245-2256.
Hanifin, J.M. et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association Administrative Regulations for Evidence-Based Clinical Practice Guidelines. J. Am. Acad. Dermatol. 2004, 50, 391-404.
Helgadottir, A. et al. The Gene Encoding 5-Lipoxygenase Activating Protein Confers Risk of Myocardial Infarction and Stroke. Nat. Genet. 2004, 36(3), 233-239.
Helgadottir A. et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006, 38, 68-74.
Huang L, et al. Molecular and Biological Characterization of the Murine Leukotriene B4 Receptor Expressed on Eosinophils. J. Exp. Med. 1998, 188(6), 1063-1074.
Hwang, S.W. et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. USA 2000, 97(11), 6155-6160.
Ikai, K. Psoriasis and the Arachidonic Acid Cascade, Jour. Of Derm. Sci., 1999, 21, 135-146.
Jala, V.R. et al. Leukotrienes and Atherosclerosis: New Role for Old Mediators. Trends Immunol. 2004, 25(6), 315-322.
Kachur, J.F. et al. Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a Potent and Selective Inhibitor of Leukotriene A4Hydrolase II: In Vivo Studies. J. Pharmacol. Exp. Ther. 2002, 300(2), 583-587.
Klein, A. et al. Stem Cell Factor Plays a Major Role in the Recruitment of Eosinophils in Allergic Pleurisy in Mice via the Production of Leukotriene B4. J. Immunol. 2000, 164(8), 4271-4276.
Laughter, D. et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J. Am. Acad. Dermatol. 2000, 43, 649-655.
Liao, T. et al. Blockade of the interaction of leukotriene B4 with its receptor prevents development of autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2006, 47(4), 1543-1549.
Libby, P. Inflammation in Atherosclerosis. Nature (London) 2002, 420(6917), 868-874.
Miyahara N. et al. Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergy Intl. 2006, 55(2), 91-97.
Munafo, D.A. et al. Leukotriene A4 Hydrolase in Human Bronchoalveolar Lavage Fluid. J. Clin. Invest. 1994, 93(3), 1042-1050.
Nakae, H. et al. Relationship between cytokines and leukotriene B4 in sepsis. Res. Commun. Chem. Pathol. Pharmacol. 1994, 83(2), 151-156.
Nathan, C. Points of Control in Inflammation. Nature (London) 2002, 420(6917), 846-852.
Alestas, T. et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J. Mol. Med. 2006, 84(1), 75-87.
Andoh, T. et al
Bembenek Scott D.
Eccles Wendy
Gomez Laurent
Grice Cheryl A.
Kearney Aaron M.
Janssen Pharmaceutica NV
Willis Douglas M
Wilson James O
LandOfFree
Aryl-substituted bridged or fused diamines as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-substituted bridged or fused diamines as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-substituted bridged or fused diamines as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658118